Cnidimol A is primarily studied for its anti-inflammatory and neuroprotective properties. It has shown potential in inhibiting key inflammatory mediators such as nitric oxide (NO), prostaglandin E2 (PGE2), and cytokines like TNF-α and IL-6 in microglial cells, suggesting a role in managing neuroinflammatory and chronic inflammatory conditions. Research indicates it may help protect neuronal cells from oxidative stress and inflammation-related damage, making it a candidate of interest in the development of therapies for neurodegenerative diseases like Alzheimer’s and Parkinson’s, as well as chronic conditions such as rheumatoid arthritis and type 2 diabetes. Additionally, its ability to modulate signaling pathways such as NF-κB and MAPK highlights its significance in cellular regulation and immune response control. Preliminary studies also explore its anti-cancer potential, particularly in inhibiting the proliferation of certain cancer cells through the induction of apoptosis. While still in the preclinical research phase, Cnidimol A serves as a lead compound for designing new therapeutic agents.